Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) ...

The biotech company said it expects between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous ...

Moderna 's ( MRNA -21.95%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...

Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...

Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Moderna lost more than $3 billion in maker value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Moderna ( MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine.